Aspen sees no immediate impact of India’s decision to curb drug exports
JOHANNESBURG – The deputy chief executive of South Africa’s Aspen Pharmacare said on Friday the drugmaker sees no immediate impact of India’s decision this week to restrict the export of 26 pharmaceutical ingredients due to the coronavirus outbreak.
An important supplier of generic drugs to the world, Indian drugmakers rely on China, the source of the virus outbreak, for almost 70% of the active pharmaceutical ingredients (APIs) for their medicines. Industry experts say they are likely to face shortages if the epidemic drags on.
“Certainly no immediate impact and we have only a very low exposure to any of those chemicals on that list,” deputy CEO and financial director Gus Attridge told Reuters in a telephone interview after presenting the firm’s first-half results, which were published on Thursday.
Source: iol.co.za